In September 1998, and August 2000, Trastuzumab was approved for medical use in the United States and European Union respectively. Trastuzumab is prescribed for adjuvant treatment of HER2 overexpressing node +Ve or node -Ve breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and paclitaxel/docetaxel, with docetaxel and carboplatin, and as a single agent following multi-modality anthracycline based therapy.
The trastuzumab injection 440 mg is used along with paclitaxel for first-line therapy of HER2 overexpressing metastatic breast cancer, and as a single agent for treating HER2 overexpressing breast cancer in recipients who have taken one or more chemo regimens for their metastatic disease. Trastuzumab is used along with medication cisplatin/capecitabine or 5-fluorouracil, for treating patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not taken earlier therapy for their metastatic disease.
How to Take Trastuzumab: The standard dose of Trastuzumab can be given in two ways. It can be administered by infusion, where the medicine slowly enters your blood through a drip. The initial treatment usually takes around 90 min and further treatments take around 30 min. The trastuzumab injection can also be administered by subcutaneous injection, which is an injection into your thigh that takes a few minutes (this can only be used for breast cancer).
The trastuzumab injection price in India is quite reasonable at each and every certified (ISO & WHO-GDP) wholesaler or pharmacy, the reason is generic brand; In India multiple companies is manufacturing generic version of trastuzumab innovator that's why the cost is cheaper.
The solution of trastuzumab infusion should be stored at temperature 2°C to 8°C (36°F to 46°F) for not over 24 hours prior to use. It should be discarded within twenty four hours.
